



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Emir et al**

Application No. **10/622,769**

Filed: **July 21, 2003**

Title: **Therapeutic Agent for Severe Alzheimer's Dementia**

Docket: 109536.182

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313

Preliminary Amendment

Prior to consideration of the above application on the merits, Applicants respectfully request entry of this preliminary amendment.

Amendments to the Claims begin on page 2.

Remarks begin on page 3.

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-2. (Canceled)

3. (New) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering 3.0 mg to 10 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.

4. (New) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering 10 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine hydrochloride to treat severe Alzheimer's dementia in the patient; wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.

5. (New) A method for treating severe Alzheimer's dementia in a patient in need thereof comprising administering a therapeutically effective amount of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.

6. (New) The method of claim 5, comprising administering 0.3 mg to 50 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.

7. (New) The method of claim 6, comprising administering 3.0 mg to 10.0 mg of 1-benzyl-4-(5,6-dimethoxy-1-indanon)2-yl)methylpiperidine or a pharmaceutically acceptable salt thereof to treat severe Alzheimer's dementia in the patient.

8. (New) The method of claim 5, wherein severe Alzheimer's dementia is characterized by a score of less than 10 on the Mini-Mental State Examination.

9. (New) The method of claim 8, wherein severe Alzheimer's dementia is characterized by a score of 5 to 9 on the Mini-Mental State Examination.